🌟 Summary - Lung 🫁 & Solid tumors 👤 📍 ADCs 📍 BsAbs 📍 I-Os 📍 Cancer Vaccines 📍 Oncolytic Viruses 📍 CAR-T cells 📍 TILs 🔈 References are numerous. 1/22

What an outstanding achievement for our physics department. They are truly the heart and soul of NWCC radiotherapy services. Well done 👏👏👏 Western Trust UKAS

First prospective data of SBRT for early stage NSCLC in pts with interstitial lung disease 👉 risk of treatment-related mortality 7.7% 👉 median OS 25mo 👍 prespecified acceptability thresholds for toxicity & efficacy met 👏 David Palma, MD, PhD and colleagues jamanetwork.com/journals/jamao…

Consensus guidelines on the diagnosis and management of RT pneumonitis ▶️ Delphi consensus ▶️Practical guide to assess risk in individual patients ▶️unmet need-> clarify the relationship between RT-drug-induced pneumonitis + optimal management strategies sciencedirect.com/science/articl…

Day 1 #ASCO24 Highlights: 1. #CROWN: Lorlatinib in ALK mNSCLC 2. #PALOMA3: SC #Amivantamab in EGFR mNSCLS 3. #MARIPOSA: Ami in EGFR mNSCLC 4. #GlobalOncCoP Inas Abuali, MD 5. #SocialMedia: Leveraging this Fumiko Ladd Chino, MD, FASCO Eric K. Singhi, MD #OncTwitter #MedEd #MedTwitter ASCO #lcsm 1/6

Impressive increase in PFS with consolidation osimertinib after CRT for pts w unresectable stage III lung cancer. Crossover on progression 82% higher than in most other studies. OS far from mature. Will be adopted as a new standard where it is available I believe. #lcsm #ASCO24

TRANSMET: CT+liver transplant vs CT alone in pts with unresectable CRC liver mets - 94 pts - ⁠5-year OS in ITT: 57% in CT+LT vs 13% in CT arm (HR 0.37,p=0.0003) - 74% of transplanted pts had recurrences in one or more organs. - anybody else feeling like🤯🤯🤯🤯? #ASCO24

📢🚨#ASCO24 plenary David R. Spigel, MD, FASCO - pivotal ADRIATIC ph III trial; adjuvant durvalumab arm after chemoradiotherapy (cCRT) ± PCI in small cell #lungcancer; ⬆️ OS (HR 0.73), median OS 55.9 vs 33.4 for placebo. Grade 3/4 AEs in 24.3% vs 24.2%. 💥Practice changing!!! #radonc #lcsm

The new standard of care is consolidation immunotherapy for limited stage small cell lung cancer & the first systemic therapy advance for limited small cell in ~50yrs. Allied to Laura we had fun on the ASCO non-metastatic NSCLC/SCLC/meso track committee this year! #lcsm #ASCO24

Osimertinib use associated with nutritional deficiencies ❗️Significant deficiencies of Vit B, Vit D, Iron, Vit B12 ❓May reflect GI side effects of drug 🤔 Should screen for these during Osimertinib treatment: quick and cheap to do #ASCO24 #LCSM

NISO educational meeting in the NWCC. ESMO updates, frailty, SABR and protons

Northern Ireland Society of Oncology (NISO) Autumn scientific meeting. A wonderful afternoon with colleagues from all over Northern Ireland. Lovely updates with a bit of humour. #NWCC #NISO #NICC #westernHSCTrust

Special thanks for our colleagues from Clattebridge Cancer Centre and the Christie @CobbenDavid Khalid Abutaleb who made a special appearance in the Autumn Scientific meeting of Northern Ireland Society of Oncology. The Clatterbridge Cancer Centre

Incredible study on HNSCC ENI now published in Journal of Clinical Oncology Randomized-controlled trial on ENI dose de-escalation Nominal dose 50 Gy vs. 43 Gy in 34 fractions EQD2 44 Gy vs 34 Gy 6 fractions per week, **NO CHEMOTHERAPY** ascopubs.org/doi/full/10.12…

10y results of FAST FORWARD (adjuvant #breastcancer RT) trial presented at #ESTRO25 by AM Brunt. Compared to 40Gy/15, 26Gy/5: 1. Non inf for IBR (even superior?) 2. Similar recurrence free interval, breast cancer interval, OS 3. No diff in PRO or toxicity Clearly 26/5 SOC for

🚨10y results of HYPO RT PC at #ESTRO25 Hypofractionated #prostatecancer RT (42,7/7) vs conv fractionated RT 1. Non inferior for FFS (even better?) 2. Similar bPFS, DMFS, ADT use, OS 3. Similar GU/GI tox (except transient flare at 1y for UHF)

This paper is absolutely fantastic. It is essentially the Bible for NPC CTV delineation. Incredible contribution to the field! redjournal.org/article/S0360-…

Want to be part of shaping the future direction of RT research in the UK? An exciting opportunity has arisen to work as a research fellow within the NIHR RTTQA Group, based at Mount Vernon Cancer Centre. For more info please DM us! #radonc #rtqa nhsjobs.com/job/UK/Hertfor…

Thought provoking!

Excellent review